Phathom Pharmaceuticals, Inc. (PHAT)
Health Care ยท Pharmaceutical Preparations
Phathom Pharmaceuticals, Inc. (PHAT) is listed on Nasdaq, where its shares have traded since October 25, 2019. SentiSense covers Phathom Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Steven Basta is its chief executive officer. The company reports 371 employees, and its corporate website is www.phathompharma.com.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Latest reported results
Phathom Pharmaceuticals, Inc. reported revenue of $84.7 million for Q3 FY2026, up 71.1% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 155 institutions reported holding PHAT, with 71.7 million shares worth $778.5 million in aggregate. The largest reported holders were Frazier Life Sciences Management, Medicxi Ventures Management (Jersey) and BlackRock. Of the 5 largest reported holders, 2 added shares, 1 reduced its position and 2 held their positions unchanged during the quarter.
More on PHAT
- PHAT sentiment: whether news and social coverage of Phathom Pharmaceuticals, Inc. leans bullish or bearish, and the stories driving it.
- PHAT ownership: all 155 reporting institutions, plus insider and congressional trades.
- PHAT financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for Phathom Pharmaceuticals, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Phathom Pharmaceuticals, Inc. do?
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases.
What sector is PHAT in?
SentiSense classifies Phathom Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does PHAT stock trade?
Phathom Pharmaceuticals, Inc. (PHAT) is listed on Nasdaq, where its shares have traded since October 25, 2019.
Who is the CEO of Phathom Pharmaceuticals, Inc.?
Steven Basta is the chief executive officer of Phathom Pharmaceuticals, Inc..